As insurers restricted coverage of behavioral pain therapy, biopharmaceutical makers sensed a possibility. Pharmaceutical innovation propagated extended-release formulations, transdermal patches, nasal sprays, and oral dissolving strips. Medical gadget manufacturers drove a proliferation of novel pa